www.nature.com/nrcardio NEWS & VIEWS from the Look AHEAD trial that focusing on caloric restriction might not be the mostefficient approach. Rather, controllin g the intake of refined carbohydrates and sugar (including sugar-sweetened beverages) and limiting salt intake are the simplest and possibly most-relevant dietary recommendations. A large increase in energy expenditur e generated by regular physical activity and exercise not only has a powerful effect of glycaemic control, but also contributes to the m obilization of harmful visceral and ectopic fat, and improves all markers of cardio vascular health.
Physical activity and exercise could work if we give lifestyle a chance. One key remaining question is how to permanently improve the physical activity levels and nutritional habits of patients in a society that makes sedentary behaviour and overconsumption of poor-quality and highly processed foods the easy choices. For clinicians, prescribing drugs is a simple option and does save lives. However, we should also strive to improve the quality of these spared years for our patients, thereby helping to relieve heavily solicited and sa turated health-care resources. 
ACUTE CORONARY SYNDROMES
Blood transfusion in patients with acute MI and anaemia
Matthew W. Sherwood and Sunil V. Rao
In a meta-analysis of predominantly observational data, blood transfusion was independently associated with adverse outcomes in patients with myocardial infarction. These findings are consistent with previously published research, but clinical application of these data is hindered by the lack of prospective, randomized trials and the inherent bias in observational studies. The appropriate use of blood transfusio n for patients with acute myocardial infarctio n (MI) and anaemia remains contro versial.
Chatterjee and colleagues performed a meta-analysis of studies to determine the association between blood transfusion and outcomes among patients with MI, and found that transfusion was associated with an increase in all-cause mortality and recurrent infarction. 1 This study raises many questions, but two are particularly important. Why would trans fusion be a ssociated with harm among patients with acute MI? Is the study by Chatterjee sufficient to guide clinical practice?
To address these questions, we must review the pathophysiology of MI and the role that anaemia might have in determining outcomes. MI is a thrombotic event that is managed with a combination of antithrombotic therapy and invasive procedures, such as cardiac catheterizatio n, percutaneous coronary intervention, or CABG surgery. This combination of treatment strategies places patients at risk of bleeding and subsequent anaemia. In addition, anaemia itself is known to e xacerbate cardiac ischaemi a, 2 thus creat ing a vicious cycle: treatment increases the risk of anaemia, which in turn can increase the risk of ischaemia. An obvious treatment option in the setting of either bleeding or anaemia is blood transfusion, because raising the haemoglobin content should, in theory, increase oxygen delivery to vulnerable myocardium.
However, little high-quality data exist to guide either when or how much blood should be transfused in patients with MI. Studies indicate that up to 10% of patients with MI receive a transfusion during hospitalization, 3 but risks are associated with transfusio n of red blood cells, such as transmission of infectiou s agents, transfusion-associated circulatory overload, and transfusion-related lung injury. 4 In addition, data suggest that packed red cells are rapidly depleted of nitric oxide during storage. 4 This 'storage lesion' might reduce the ability of transfused blood to increase oxygen delivery and, therefore, might potentiat e ischaemia, rather than reduce it, by inducin g v asoconstriction and platelet activation.
Some published, prospective, ra ndomized trials have examined 'transfusion thresholds' (that is, the level of h aemoglobin at which transfusion should be given to maximize benefit and minimize harm), but most of these studies included a variety of critical illnesses, and very few patients with acute ischaemic heart disease. Most of the literature focusing on transfusio n strategies in this latter group includes either small, pilot, ra ndomized trials or observational studies. The only published prospective, randomized trial is the CRIT Randomized Pilot trial. 5 In this study, the investigators randomly allocated 45 patients with MI, either with or without ST-segment elevatio n, and a haematocri t level ≤30% within 72 h of admissio n, to either a liberal strategy (t ransfusion to maintain the haematocrit level at 30-33%) or a conservativ e strateg y (transfusion to maintain the haematocri t level at 24-27%). The trial was not powered for any particular end point, but the rate of in-hospita l death, recurrent MI, or congestive heart failure was compared between the groups. The rate of the compo site end point was significantly higher among patients assigned to the liberal arm than in those allocated to the conservative arm (38% versus 13%; P = 0.046). This differenc e was driven by a higher incidenc e of heart failure with liberal transfusion. No significant differ ences occurred in the incidence of in-hospital mortality or recurrent MI.
This randomized trial was part of the meta-analysis performed by Chatterjee and co-workers, 1 which also incorporate d nine other observational studies that included post-hoc analyses of randomized trials examining antithrombotic therapies for MI, administrative data, and registries. The combi nation of these studies yielded a sample size of >203,000 patients. Two o utcomes were assessed: all-cause mortality and MI reported after the longest-available duration of follow-up. The researchers went to great lengths to test for publication bias, using funnel plots, Egger regression tests, and trim-and-fill methods for odds ratio calculations, and found no evidence of bias. They also used meta-regression and sequential analyses to validate the findings statistically. After applying robust metaanalytic techniques, the investigator s found that blood transfusion was independentl y associated with an increased risk of allcause mortality (relative risk [RR] 2.91, 95% CI 2.46-3.44, P <0.001), and recurrent MI (RR 2.04, 95% CI 1.06-3.93, P = 0.03). Are these data sufficient to guide clinica l practice? Should blood transfusion be withheld from patients with acute MI and anaemia? The short answer to both quest ions is 'no'; the longer answer requires a review of the primary limitation of observational studies examining the role of transfusion. In an observational analysis, the association between transfusion and cardiovascular outcomes can be affected by confounding by indication-the idea that patients receiving an indicated therapy (for example, blood transfusion) might be more likely to experience an adverse outcome unrelated to the therapy. In the setting of an MI, patients with anaemia might have a higher risk of death and recurrent ischaemia, and are also more likely to receive a transfusion. The risk of adverse outcomes with anaemia might overwhelm any benefit of transfusion, thus creating an association between transfusion and the outcome that might not be causal. In most, if not all, of the observational studies included in the Chatterjee analysis, multivariable regression or propensity matching techniques were used to adjust for confounding variables, and although the researchers used meta-regression to overcome potential biases, unmeasured confounding is un doubtedly still present.
Given the lack of high-quality data from randomized trials, the American Association of Blood Banks has been hesitan t to make strong recommendations for or against a particular transfusion strategy in patients with MI (Box 1). 6 Moreover, the strength of their recommendation is listed as "uncertain", which leaves clinicians in a quandary about how best to treat patients with MI and anaemia. What clinicians can-and should-do, however, is to minimize the risk of bleeding and subsequent transfusion during treatment for MI. This aim can be accomplished by assessing a patient's risk of bleedin g using available risk models, 7 appropri ately adjusting the dose of antithrombotic medicatio ns, 8 using antithrombin agents associated with reduced bleeding risk, 9 and using radial artery access for cardiac catheterizatio n and percutaneous coronary intervention whenever possible. 10 Ultimately, given the prevalence of MI, the risk associated with anaemia, the frequent use of transfusio n in these patients, and the lack of high-quality data, a prospective, randomized trial of tr ansfusion strategies is needed to guide clinical practice.
